Inovatyvi Medicina

Project Key Data

Full title of the project:
Remote Embolisation Demonstrator

Short name of the project:

Date of the award:
August 2022

Project duration:
9 months

Lead Company:
Inovatyvi Medicina (Lithuania)

Project Partner(s):

Patient1st Consult (Germany)


Endovascular embolization techniques are becoming more and more popular because of their minimal invasive approach as well as effectiveness in constantly increasing list of indications. Started as palliative mode of treatment for bleeding patients, it has become the gold standard for most of the intracerebral vascular diseases and powerful adjunct for cancer patients as locoregional therapy. The use of embolization procedures is limited to major hospital cath-labs and have limited availability in urgent situations, especially in remote areas. Urgency is of particular importance in cases where the source of bleeding is intracerebral aneurysm or arterio-venous malformation. That is why endovascular embolization procedures should be performed on site 24/7, which is impossible in the real world. Another disadvantage of endovascular embolization techniques is the exposure of the patient and medical team to extremely high amount of radiation, which in turn cause medical personnel disabilities due to occupational hazards.
UAB Inovatyvi Medicina has developed an innovative endovascular robot Sentante – SMART and SENSING technology which augments surgeon’s actions and allows performing endovascular procedures remotely. Bringing experience from previously developed robotic solutions for neuro-diagnostic medical equipment used by NASA and Germain Aerospace centre, the developers of the technology have successfully created and tested the Sentante system – robotic system capable to perform an entire endovascular procedure from the very beginning till the end.
Sentante is the only robotic system which was adopted for embolotherapy application within the previous DIH HERO TTE project successfully implemented by the company. The developed control solutions, interfaces and disposable components enable robotic embolotherapy procedure and open up new market niche for the company and it’s partners. We aim to demonstrate feasibility of this innovative robotic solution to the end-users and industry partners in one of the major healthcare application domains – Interventional Robotics.
The primary target market of Sentante system is more than 3.000 cath labs performing endovascular procedures in EU (more than 200 000 endovascular embolization procedures annually in EU). Using “razor and blade” revenue model and continuous revenue stream from sterile disposable components per embolotherapy procedure the company expects to quickly scale up its sales in EU aiming for expansion to US and Worldwide markets with total market potential exceeding €4 billion.
A multidisciplinary team with vast experience in medical sciences, medical device development, robotics, mechanical and electronic engineering, product design, commercialisation and business development has joined forces for the implementation of the project aiming to bring the technology to clinical practice for benefit of patients, physicians and hospitals and exploit this niche market commercial opportunity.